Just caught Relay Therapeutics jumping 19% on earnings—stock hit a new 52-week high at $10.98 today. Pretty solid move for a clinical-stage biotech. Here's what caught my attention.

They managed to narrow their Q4 loss to $54.9M from $76M a year ago, and full-year 2025 losses came in at $276.5M versus $337.7M in 2024. More importantly, they're actually generating revenue now—$15.4M for the year, up from $10M in 2024, mainly through their Elevar licensing deal. That's the kind of trajectory you want to see.

The real story though is their pipeline momentum. Zovegalisib, their lead candidate, is running a Phase 3 trial for HR+/HER2- metastatic breast cancer with PI3Ka mutations. They're planning to release triplet combination data and frontline Phase 3 plans in 2026—basically how to jump a relay from their current position to actual commercialization readiness. They've also got initial data coming in H1 2026 from their vascular anomalies trial, which is interesting because it opens up a whole different patient population.

Beyond that, they're pushing RLY-8161, an NRAS-selective inhibitor for solid tumors, and working on a non-inhibitory chaperone program for Fabry disease. The Lirafugratinib program got out-licensed to Elevar, so that's generating milestone payments flowing back to them.

Cash position looks solid too—$554.5M in cash and investments, enough to fund operations through 2029 according to management. CEO Sanjiv Patel is calling 2026 a pivotal year, and honestly, with multiple clinical readouts lined up, they've got real catalysts ahead. The stock's been ranging between $1.77 and $10.98 over the past year, so there's been volatility, but today's move suggests the market is buying into the story. Worth watching if you're into biotech plays with near-term milestones.